Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non‐small cell lung cancer—expression of an RNA‐binding protein, Musashi1, as a marker for the tailored gene therapy
- 6 September 2006
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 8 (11) , 1329-1340
Abstract
Background: Oncolytic herpes vectors like G207 have shown considerable promise in the treatment of solid tumors, but their potency must be enhanced for the full achievement of therapeutic efficacy. Deletion of the innate γ34.5 gene made these vectors extremely safe, but their efficacy was also severely attenuated. Use of tumor‐specific promoters is one method to direct toxicity and enhance efficacy against tumors. Recently, Musashi1 has been shown expressed in some tumor tissues.Methods: Eleven human cancer cell lines including five non‐small cell lung cancers (NSCLCs) were investigated. Musashi1 mRNA expression was examined by RT‐PCR analysis. Western blotting was also performed. Transcriptional activity of P/musashi1 in NSCLCs was assayed by GFP reporter plasmids. Then we constructed a defective amplicon vector containing musashi1 promoter/ICP34.5 with G207 as helper virus (dvM345). In vitro cytotoxicity against NSCLCs and growth characteristics of helper virus were examined. A Lu‐99 subcutaneous tumor model was used in an animal study. The tumor volume treated with G207 alone or dvM345 was measured.Results: Musashi1 mRNA was detected in four cell lines. Two in five NSCLCs were positive, and P/musashi1 was proved functional within them. Against these cell lines, dvM345 showed enhanced cytotoxicity, and helper viral growth was augmented. A subcutaneous tumor study confirmed the enhanced therapeutic efficacy of G207 by dvM345 without compromising safety.Conclusions: These results suggest that Musashi1 might be involved in the development of several carcinomas including NSCLC. In the context of oncolytic herpes vector strategy, the P/musashi1‐ICP34.5 method could be used for the treatment of cancers expressing Musashi1. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 53 references indexed in Scilit:
- Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of γ34.5-mediated virulenceGene Therapy, 2005
- An Oncolytic HSV-1 Mutant Expressing ICP34.5 under Control of a Nestin Promoter Increases Survival of Animals even when Symptomatic from a Brain TumorCancer Research, 2005
- A putative human breast stem cell population is enriched for steroid receptor-positive cellsDevelopmental Biology, 2005
- Proliferative activity andin vitro replication of HSV1716 in human metastatic brain tumoursThe Journal of Gene Medicine, 2003
- Treatment of Human Breast Cancer in a Brain Metastatic Model by G207, a Replication-Competent Multimutated Herpes Simplex Virus 1Human Gene Therapy, 1998
- A Novel Multiply-Mutated HSV-1 Strain for the Treatment of Human Brain TumorsHuman Gene Therapy, 1997
- Enhancement of Gene Therapy Specificity for Diffuse Colon Carcinoma Liver Metastases with Recombinant Herpes Simplex VirusAnnals of Surgery, 1996
- Gene Transfer into Experimental Brain Tumors Mediated by Adenovirus, Herpes Simplex Virus, and Retrovirus VectorsHuman Gene Therapy, 1994
- Current Treatment of Unresectable Lung CancerMayo Clinic Proceedings, 1993
- Expression of a functional foreign gene in adult mammalian brain following in Vivo transfer via a herpes simplex virus type 1 defective viral vectorMolecular and Cellular Neuroscience, 1991